Latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome – Pipeline Review, H1 2018, provides an overview of the Myelodysplastic Syndrome pipeline landscape.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 1, 13, 69, 51, 3, 19 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 8, 9, 3, 2 and 2 molecules, respectively.

Myelodysplastic Syndrome pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Myelodysplastic Syndrome are: 4SC AG, AbbVie Inc, Actinium Pharmaceuticals Inc, ADC Therapeutics SA, Aeglea BioTherapeutics Inc, Affimed GmbH, Altor BioScience Corp, Amgen Inc, Angiocrine Bioscience Inc, ARA Healthcare Pvt Ltd, Ariad Pharmaceuticals Inc, Array BioPharma Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, Autolus Ltd, Bellicum Pharmaceuticals Inc, Bexion Pharmaceuticals LLC, Bio-Cancer Treatment International Ltd, Bio-Path Holdings Inc, BioSight Ltd, Bristol-Myers Squibb Co, Calithera Biosciences Inc, CanBas Co Ltd, CARsgen Therapeutics Ltd, Cellectis SA, Cellestia Biotech AG, Cellular Biomedicine Group Inc, Cielo Therapeutics Inc, Cyclacel Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Deciphera Pharmaceuticals LLC, Eli Lilly and Co, Enlivex Therapeutics Ltd, Epizyme Inc, Erytech Pharma SA, Fate Therapeutics Inc, Formula Pharmaceuticals Inc, Gamida Cell Ltd, Gilead Sciences Inc, GlaxoSmithKline Plc, iDD biotech SAS, ImmunoGen Inc, Immunomedics Inc, Incyte Corp, Interprotein Corp, Jasco Pharmaceuticals LLC, Jazz Pharmaceuticals Plc, Johnson & Johnson, Juno Therapeutics Inc, Karyopharm Therapeutics Inc, Kiadis Pharma NV, Kiromic Inc, Kite Pharma Inc, Les Laboratoires Servier SAS, Lin Bioscience Inc, medac GmbH, Medivir AB, Millennium Pharmaceuticals Inc, Miltenyi Biotec GmbH, Mitsubishi Tanabe Pharma Corp, Molecular Templates Inc, NantKwest Inc, NBE-Therapeutics AG, Nimbus Therapeutics LLC, Nohla Therapeutics Inc, Novartis AG, NovImmune SA, Omeros Corp, OncoTartis Inc, OncoTherapy Science Inc, OSE Immunotherapeutics, Pascal Biosciences Inc, Pfenex Inc, Pfizer Inc, Pharma Mar SA, Polyphor Ltd, Protheragen Inc, PTC Therapeutics Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sareum Holdings Plc, Seattle Genetics Inc, SELLAS Life Sciences Group Inc, Shire Plc, Spectrum Pharmaceuticals Inc, Sun Pharma Advanced Research Company Ltd, SYNIMMUNE GmbH, Syros Pharmaceuticals Inc, Takara Bio Inc, TCR2 Therapeutics Inc, Tolero Pharmaceuticals Inc, TRACON Pharmaceuticals Inc, Trillium Therapeutics Inc, Verastem Inc, Xbrane Biopharma AB, Xspray Pharma AB, ZIOPHARM Oncology Inc

Request for a Sample Copy of this Research Report at:


  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome.
    2. The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Myelodysplastic Syndrome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome

Browse full Report at:

Reasons to buy this Report:

1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
2. Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome.
Classify potential new clients or partners in the target demographic.
3. Develop tactical initiatives by understanding the focus areas of leading companies.
4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
5. Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics.
6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.